# Alpramil 5 mg/50 mg tablets for dogs weighing at least 0.5 kg

Authorised

- Praziquantel
- Milbemycin oxime

## Product identification

**Medicine name:**
Alpramil 5 mg/50 mg tablets for dogs weighing at least 0.5 kg

**Active substance:**
Praziquantel

Milbemycin oxime

**Target species:**
Dog

**Route of administration:**
Oral use

## Product details

**Active substance and strength:**
Praziquantel
50.00 milligram(s) / 1.00 Tablet

Milbemycin oxime

5.00 milligram(s) / 1.00 Tablet

**Pharmaceutical form:**
Tablet

**Anatomical therapeutic chemical veterinary (ATCvet) codes:**
QP54AB51

**Legal status of supply:**
Veterinary medicinal product subject to veterinary prescription

**Authorisation status:**
Valid

**Authorised in:**
Croatia

**Package description:**
Box with 25 OPA/Aluminium/PVC-Aluminium blisters each containing 4 tablets.
Box with 25 OPA/Aluminium/PVC-Aluminium blisters each containing 2 tablets.
Box with 25 OPA/Aluminium/PVC-Aluminium blisters each containing 1 tablet.
Box with 10 OPA/Aluminium/PVC-Aluminium blisters each containing 4 tablets.
Box with 10 OPA/Aluminium/PVC-Aluminium blisters each containing 2 tablets.
Box with 10 OPA/Aluminium/PVC-Aluminium blisters each containing 1 tablet.
Box with 1 OPA/Aluminium/PVC-Aluminium blister containing 4 tablets.
Box with 1 OPA/Aluminium/PVC-Aluminium blister containing 2 tablets
Box with 1 OPA/Aluminium/PVC-Aluminium blister containing 1 tablet.

## Additional information

**Entitlement type:**
Marketing Authorisation

**Legal basis of product authorisation:**
Hybrid application (Article 13(3) of Directive No 2001/82/EC)

**Marketing authorisation holder:**
Alfasan Nederland B.V.

**Marketing authorisation date:**
7/04/2022

**Manufacturing sites for batch release:**
Lelypharma B.V.
Alfasan Nederland B.V.

**Responsible authority:**
Ministry Of Agriculture Veterinary And Food Safety Directorate

**Authorisation number:**
UP/I-322-05/22-01/254

**Date of authorisation status change:**
23/06/2025

**Reference member state:**
Netherlands

**Procedure number:**
NL/V/0364/004

**Concerned member states:**
Belgium Bulgaria Croatia Cyprus Czechia Estonia Finland France Germany Greece Hungary Iceland Ireland Italy Latvia Lithuania Luxembourg Norway Poland Portugal Romania Slovakia Slovenia Spain

United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

## Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Combined File of all Documents

English (PDF)
Published on: 14/01/2026
Download

NL_V_0364_004-006_DC Milpramax tablets for dogs-Final PuAR.pdf